Astrazeneca Pharma India Limited

BSE: 506820 NSE: ASTRAZEN
Astrazeneca Pharma India Limited - pharma in Bangalore, Karnataka, India. FY 2026 financials & compliance.
CIN L24231KA1979PLC003563 Incorporated 11 July 1979 ROC Bangalore HQ Bangalore, Karnataka, India
Active Listed - NSE: ASTRAZEN · BSE: 506820 Public Limited Company pharma
Data last updated
Market Cap
₹16,478 Cr
ASTRAZEN · NSE
Share Price
₹6,505.00
-1.30% today
Revenue
₹2,276 Cr
FY 2025-26 · +29.5% YoY
EBITDA
₹257 Cr
Margin 11.3%
Net Profit
₹191 Cr
FY 2025-26 · +9.2% YoY
P/E (TTM)
96.6x
P/B 19.2x
ROE
22.8%
ROCE 27.9%
Debt / Equity
0.09
Interest cover 2.0x

About Astrazeneca Pharma India Limited

Data last updated: 25 September 2026

Astrazeneca Pharma India Limited is a public limited company based in Bangalore, Karnataka, India, a subsidiary of Astrazeneca Pharmaceuticals Ab. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 11 July 1979, the company has been in operation for over 47 years.

Registered with ROC Bangalore under CIN L24231KA1979PLC003563. Listed on BSE: 506820 and NSE: ASTRAZEN.

Capital: an authorised share capital of ₹5 Cr and a paid-up capital of ₹5 Cr. Formerly known as Astra Idl Limited. It is led by directors including Shilpa Divekar Nirula and Ashok Revathy.

Last AGM: 14 August 2025. Financial statements filed for year ended 31 March 2025. Office: Block N1 12Th Floor Manyata Embassy Business Park Rachenahalli Outer Ring Road, Bangalore, Karnataka, India – 560045.

As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹2,275.58 Cr, a growth of 32.59% compared to the previous year. The net worth stands at ₹872.79 Cr (up 13.3% YoY). Total assets are valued at ₹1,021.2 Cr (up 24.32% YoY).

The company has a workforce of approximately 935 employees as per the latest available data. It operates as a subsidiary of Astrazeneca Pharmaceuticals Ab.

As per MCA filings, the company has satisfied charges of ₹62.5 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website astrazeneca.in.

Company Details of Astrazeneca Pharma India Limited
CIN L24231KA1979PLC003563
Registration Number 003563
Incorporation Date 11 July 1979
ROC Bangalore
Listing Status Listed (BSE: 506820, NSE: ASTRAZEN)
Company Status Active
Date of Last AGM 14 August 2025
Date of Balance Sheet 31 March 2025
Parent Company Astrazeneca Pharmaceuticals Ab
Compliance Status Active Compliant
Key People
Praveen Rao Akkinepally Managing Director Bhavana Agrawal Whole-Time Director Shilpa Divekar Nirula Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    astrazeneca.in
  • Social Media
  • Registered Address
    Block N1 12Th Floor Manyata Embassy Business Park Rachenahalli Outer Ring Road, Bangalore, Karnataka, India – 560045
  • Industry
    Pharma, Drug Formulation & Development
Company report
Astrazeneca Pharma India Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Astrazeneca Pharma India Limited report

Financials, compliance, directors, charges, ownership and filings for Astrazeneca Pharma India Limited in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Astrazeneca Pharma India Limited

Astrazeneca Pharma India Limited has one previous CIN (Corporate Identification Number): L85110KA1979PLC003563. The current CIN is L24231KA1979PLC003563, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L24231KA1979PLC003563 Current
L85110KA1979PLC003563 Previous

Business Activity of Astrazeneca Pharma India Limited

Astrazeneca Pharma India Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
Premium access

Business activity turnover details for Astrazeneca Pharma India Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Astrazeneca Pharma India Limited

Astrazeneca Pharma India Limited is audited by Price Waterhouse & Co Chartered Accountants LLP for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.

Name Status Appointment Date Cessation Date
Price Waterhouse & Co Chartered Accountants LLP Locked Locked Locked
Premium access

Complete auditor history for Astrazeneca Pharma India Limited

Appointment status, appointment dates, cessation dates, and historical auditor changes require an active report plan.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Board of Directors of Astrazeneca Pharma India Limited

Astrazeneca Pharma India Limited is currently managed by 6 directors, with 35 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Shilpa Divekar Nirula
Also directs: Astrazeneca Pharma India Limited, Agvaya Llp, Gmm Pfaudler Limited and 3 more
Director 29 Dec 2021 4 Years 8 Months Current
Ashok Revathy
Also directs: Strategygarage Solutions Llp, Astrazeneca Pharma India Limited, Sansera Engineering Limited and 5 more
Director 02 Dec 2016 9 Years 9 Months Current
Praveen Rao Akkinepally
Also directs: Astrazeneca Pharma India Limited, Astrazeneca India Private Limited
Managing Director 01 Jul 2025 1 Years 2 Months Current
Monica
Also directs: Astrazeneca Pharma India Limited, H.G. Infra Engineering Limited (Part Ix), Dreamfolks Services Limited and 1 more
Director 25 Sep 2024 2 Years 0 Months Current
Bhavana Agrawal
Also directs: Astrazeneca Pharma India Limited
Whole-Time Director 08 Feb 2024 2 Years 7 Months Current
Hooi Bien Chuah
Also directs: Astrazeneca Pharma India Limited
Director 09 Nov 2023 2 Years 10 Months Current
View all directors

Financials of Astrazeneca Pharma India Limited FY 2025-26 filings available

Astrazeneca Pharma India Limited reported revenue of ₹2,275.58 Cr (up 32.59% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Standalone
Revenue
₹2,276 Cr
+32.6% YoY
EBITDA
₹257 Cr
+63.4% YoY
Profit After Tax
₹191 Cr
+9.2% YoY
Net Worth
₹873 Cr
+13.3% YoY
Total Assets
₹1,021 Cr
+24.3% YoY
Total Debt
₹111 Cr
+209.7% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,2761,7161,2961,003806814832
Revenue growth+29.5%+40.3%+26.5%+22.1%+6.1%-4.6%+8.2%
EBITDA25715718412586.18135121
EBITDA margin+11.3%+9.2%+14.2%+12.5%+10.7%+16.7%+14.5%
Profit before tax25215622013483.04127114
Net profit19117514912659.5591.7272.03
Net profit margin+8.4%+10.2%+11.5%+12.6%+7.4%+11.3%+8.7%
EPS (₹)75.0146.3064.6039.7224.6437.3228.88
Balance sheet
Total assets1,021821723604528475382
Net worth873770712589511456364
Total debt11135.734.597.218.6312.1411.84
Cash & bank449537506500448352253
Net working capital772646577455377319218
Cash flow
Cash from operations(15.14)65.3627.8758.2910110587.42
Cash from investing18.6930.8021.7418.114.74173(171)
Cash from financing(91.97)(65.59)(44.38)(24.48)(9.46)(8.97)(6.36)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue683579612559526480440408
Revenue growth (YoY)+29.7%+20.4%+38.9%+37.0%+35.8%+25.4%+44.0%+31.2%
Other income9.235.956.616.1711.2416.157.988.15
Total expenses634519567489446400397355
EBITDA48.7059.8344.8369.8980.7580.6943.4452.54
EBITDA margin+7.1%+10.3%+7.3%+12.5%+15.3%+16.8%+9.9%+12.9%
Depreciation5.235.603.842.5716.5717.699.079.32
Interest1.952.041.060.670.720.680.330.34
Profit before tax50.7558.1446.5472.8274.7078.4742.0251.03
Tax12.8213.2613.9518.6018.8720.2211.1712.60

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 25 Sep 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue683579612559526480440408
Revenue growth (YoY)+29.7%+20.4%+38.9%+37.0%+35.8%+25.4%+44.0%+31.2%
Other income9.235.956.616.1711.2416.157.988.15
Total expenses634519567489446400397355
EBITDA48.7059.8344.8369.8980.7580.6943.4452.54
EBITDA margin+7.1%+10.3%+7.3%+12.5%+15.3%+16.8%+9.9%+12.9%
Depreciation5.235.603.842.5716.5717.699.079.32
Interest1.952.041.060.670.720.680.330.34
Profit before tax50.7558.1446.5472.8274.7078.4742.0251.03
Tax12.8213.2613.9518.6018.8720.2211.1712.60
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,2761,7161,2961,003806814832
Revenue growth+29.5%+40.3%+26.5%+22.1%+6.1%-4.6%+8.2%
Other income28.4940.6351.2326.1014.7612.8412.99
Total expenses2,0191,5591,111878719678711
Employee cost264257241259230220217
EBITDA25715718412586.18135121
EBITDA margin+11.3%+9.2%+14.2%+12.5%+10.7%+16.7%+14.5%
Depreciation28.5839.9914.9416.2616.9520.1318.58
Interest4.491.461.200.630.951.091.14
Profit before tax25215622013483.04127114
Tax64.6840.6258.0334.8121.4433.7941.76
Net profit19117514912659.5591.7272.03
Net profit margin+8.4%+10.2%+11.5%+12.6%+7.4%+11.3%+8.7%
EPS (₹)75.0146.3064.6039.7224.6437.3228.88
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital5.005.005.005.005.005.005.00
Reserves & surplus868765707584506451359
Shareholders' funds (net worth)873770712589511456364
Secured loans0.000.000.000.000.000.000.00
Unsecured loans11135.734.597.218.6312.1411.84
Total debt11135.734.597.218.6312.1411.84
Total liabilities1,021821723604528475382
Assets
Gross block185218187179169160133
Net block11764.2466.6868.8674.4980.9671.53
Capital work in progress0.000.000.271.332.204.0224.24
Investments0.000.000.000.000.000.000.00
Inventories1,027548228190140160165
Sundry debtors21418515310885.8985.1983.21
Cash & bank balances449537506500448352253
Loans & advances50.3072.2745.8637.2631.1021.4241.44
Total current assets1,7401,342933835706619542
Total current liabilities968697355380329300325
Net working capital772646577455377319218
Total assets1,021821723604528475382
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash53650650044835283.50173
Net cash from operating activities(15.14)65.3627.8758.2910110587.42
Net cash from investing activities18.6930.8021.7418.114.74173(171)
Net cash from financing activities(91.97)(65.59)(44.38)(24.48)(9.46)(8.97)(6.36)
Net change in cash(88.42)30.575.2351.9296.08269(89.74)
Closing cash449537506500448352253
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+32.6%+32.5%+29.2%+24.5%-1.0%-2.2%+14.2%
EBITDA growth+63.4%-14.8%+47.7%+44.9%-36.4%+12.2%+69.3%
PBT growth+61.3%-28.8%+63.7%+61.5%-34.7%+11.5%+56.8%
Net income growth+9.2%+17.5%+18.1%+112.0%-35.1%+27.3%+32.4%
Revenue CAGR (3Y)+31.4%+28.7%+16.8%+6.4%+3.4%+12.5%+15.2%
EBITDA CAGR (3Y)+27.2%+22.2%+10.8%+1.1%+6.5%+43.0%+48.4%
Profitability & leverage
Net income margin+8.2%+6.7%+12.5%+9.9%+7.7%+11.5%+8.7%
Return on capital employed+27.9%+32.9%+33.3%+30.5%+16.8%+29.9%+33.6%
Return on net worth+22.8%+23.6%+24.8%+23.0%+12.7%+22.7%+21.7%
Debt / equity0.090.030.010.010.020.030.02
Long-term debt / equity0.080.020.000.010.010.020.01
Interest cover1.971.250.710.581.370.951.12
Efficiency & per share
Fixed asset turnover11.318.487.075.774.905.566.58
Inventory turnover2.894.426.206.075.375.015.87
Debtors turnover11.4210.169.9410.379.429.6610.21
EPS (₹)75.0146.3064.6039.7224.6437.3228.88
Dividend per share (₹)36.0032.0024.0016.0010.002.001.00
Book value per share (₹)349.12308.14284.77235.48204.56182.47145.78
Want more history and ratios?
You're viewing the latest exchange-filed financials for Astrazeneca Pharma India Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Astrazeneca Pharma India Limited

As per the shareholding pattern for the quarter ended Jun 2026, promoters hold 75.00%, foreign institutional investors hold 2.70%, domestic institutional investors hold 6.10%, retail and other public shareholders hold 16.20% of Astrazeneca Pharma India Limited.

Promoters: 75.00%DII (Domestic Institutional): 6.10%FII (Foreign Institutional): 2.70%Retail & Others: 16.20%
Jun 2026
QUARTER
75.00% Promoters
6.10% DII (Domestic Institutional)
2.70% FII (Foreign Institutional)
16.20% Retail & Others
Promoter holding - history
Now 75.00% · Jun 2026High 75.00% · Sep 2025Low 75.00% · Sep 2025
74%74.5%75%75.5%76%Sep 2025Dec 2025Mar 2026Jun 2026Sep 2025: 75.00%Dec 2025: 75.00%Mar 2026: 75.00%Jun 2026: 75.00%75.00%75.00%
Shareholding trend - last 6 quarters
Jun 2026Mar 2026Dec 2025Sep 2025
Promoters75.00%75.00%75.00%75.00%
Public25.00%25.00%25.00%25.00%

Charges & Borrowings of Astrazeneca Pharma India Limited

Open charges
₹0
Satisfied charges
₹62.5 Cr
Breakdown by lending institutions
Il & Fs Trust Company Limited₹62.50 Cr
Latest charge details
DateLenderAmountStatus
16 Jan 2008 Il & Fs Trust Company Limited ₹62.5 Cr Satisfied

Total charge records: 1 View all charges

Employees and EPFO Compliance at Astrazeneca Pharma India Limited

Astrazeneca Pharma India Limited has a workforce of 935 employees as of Apr 07, 2024.

Employee count
935
Active EPFO establishments
2
Employee growth
-13.59%
Premium access

Employee and EPFO history for Astrazeneca Pharma India Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Astrazeneca Pharma India Limited

Premium access

GST registrations and filing compliance for Astrazeneca Pharma India Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Astrazeneca Pharma India Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Astrazeneca Pharma India Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Astrazeneca Pharma India Limited

Premium access

MSME payment history for Astrazeneca Pharma India Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Astrazeneca Pharma India Limited

Premium access

Corporate group structure for Astrazeneca Pharma India Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Astrazeneca Pharma India Limited

Premium access

MCA filings and documents for Astrazeneca Pharma India Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Astrazeneca Pharma India Limited

Directors
20 Mar 2026
Tanya Sanish was appointed as a Company Secretary on 20 Mar 2026 & has been associated with this company since 6 months 9 days.
Activity
14 Aug 2025
Astrazeneca Pharma India Limited last Annual general meeting of members was held on 14 Aug 2025 as per latest MCA records.
Directors
01 Jul 2025
Praveen Rao Akkinepally was appointed as a Managing Director on 01 Jul 2025 & has been associated with this company since 1 year 2 months.
Activity
31 Mar 2025
Astrazeneca Pharma India Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Bangalore.
Directors
25 Sep 2024
Monica was appointed as a Director on 25 Sep 2024 & has been associated with this company since 2 years 1 day.
Directors
15 Mar 2024
Bhavana Agrawal was appointed as a Cfo on 15 Mar 2024 & has been associated with this company since 2 years 6 months.

Recent News on Astrazeneca Pharma India Limited

Aliaxis welcomes Jeyamalini Natesan as CHRO
11 Dec 2023 · People Matters
Eugia Pharma gets USFDA nod for Budesonide generic
30 Nov 2023 · Thehindubusinessline

Frequently Asked Questions about Astrazeneca Pharma India Limited

Astrazeneca Pharma India Limited is an active public limited company in the pharma sector based in Bangalore, Karnataka, India. It was incorporated on 11 July 1979 (47+ years old) and is registered under CIN L24231KA1979PLC003563. Listed on BSE: 506820 and NSE: ASTRAZEN. The company has 935 employees.

Astrazeneca Pharma India Limited reported revenue of ₹2,275.58 Cr for FY 2025-26 (up 32.59% YoY) based on standalone financials.

The current directors of Astrazeneca Pharma India Limited are:

The primary industry of Astrazeneca Pharma India Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Astrazeneca Pharma India Limited is listed on both BSE (code: 506820) and NSE (symbol: ASTRAZEN).

Astrazeneca Pharma India Limited can be reached at the registered office: Block N1 12Th Floor Manyata Embassy Business Park Rachenahalli Outer Ring Road, Bangalore, Karnataka, India – 560045, or through the website astrazeneca.in.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available